戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 munoassay (EIA) for the presence of vaccinia virus antibody.
2 eir serum samples were tested for anti-Nipah virus antibody.
3 and antigen-selected human IgG1lambda rabies virus antibody.
4 ve vaccine-induced anti-feline panleukopenia virus antibodies.
5 on of screening donor plasma for hepatitis C virus antibodies.
6 2 (10%) of 223 were positive for hepatitis D virus antibodies.
7 ncephalopathy by testing for John Cunningham virus antibodies.
8 fore the diagnosis were positive for anti-JC virus antibodies.
9 us immune complexes formed with human dengue virus antibodies.
10 ed in the absence of antibody to hepatitis C virus antibodies.
11 tively, had seroprotective levels of measles virus antibodies; 100.0% and 99.6%, respectively, showed
12 ingdom blood donor screening for hepatitis C virus antibody:18 of 39 (46%) and those treated after th
13  29 tested were seropositive for hepatitis C virus antibody (31%); in total, 22 cases were seropositi
14 emonstrate a 50 to 60% prevalence of anti-JC virus antibodies, a low false-negative rate, and an asso
15 etect anti-p17 (HIV, human immune deficiency virus) antibodies (Ab) in phosphate buffered solutions (
16 ons, and positivity for anti-John Cunningham virus antibodies and antinatalizumab antibodies.
17  The case-cohort will be utilized to analyze virus antibodies and bacteriome from longitudinal plasma
18 al vaccine should target conserved influenza virus antibody and T cell epitopes that do not vary from
19 1 (10%) of 311 were positive for hepatitis C virus antibodies, and 22 (10%) of 223 were positive for
20 YLD virus does not cross-react with vaccinia virus antibodies, and it replicates efficiently in human
21 e for measles virus, mumps virus, or rubella virus antibodies, and there were no significant differen
22 epatitis B surface antigen, anti-hepatitis C virus antibody, and diabetes mellitus) (hazard ratio = 3
23 histochemical assays using a mouse anti-Zika virus antibody, and RT-PCR assays targeting the NS5 and
24 nsequence of the complex interaction between virus, antibody, and target cell.
25 Gs), and our studies on their recognition by viruses, antibodies, and glycan-binding proteins (GBPs),
26 munoassays (EIA-2 and EIA-3) for hepatitis C virus antibody (anti-HCV) are the most practical screeni
27 dy formation, and false-negative hepatitis C virus antibody (anti-HCV) tests have been reported in in
28             If the occurrence of hepatitis E virus antibody (anti-HEV) in regions where the disease i
29 ne positivity, we showed that specific Ebola virus antibodies are not widespread among NHPs.
30 ctive mechanism underlying this example of a virus-antibody arms race, illustrate the functional sign
31                This work has revealed that a virus-antibody "arms race" occurs in which a HIV-1 trans
32 uses and B cells evolve together, creating a virus-antibody "arms race." Analysis of samples from an
33 ical false-negative rate of a 2-step anti-JC virus antibody assay.
34                                  The measles virus antibody avidity indexes were high for all childre
35 ypocomplementemia and a positive hepatitis C virus antibody but negative hepatitis C virus PCR.
36          The detection of serum Epstein-Barr virus antibodies by immunofluorescence assay (IFA) is co
37 r of these (7.1%) were positive for vaccinia virus antibody by EIA.
38 dies suggest that circulating anti-influenza virus antibodies can potently modulate the magnitude and
39       Finally, we demonstrate that anti-Zika virus antibody can be sensitively and specifically detec
40                                              Virus-antibody coevolution in macaques can thus recapitu
41                           However, not every virus-antibody combination results in complete neutraliz
42 mined the three-dimensional structure of the virus-antibody complex.
43                            Two of these were virus-antibody complexes having contrasting transcriptio
44                                     For some viruses, antibody concentrations correlate with host pro
45              Among the 4 serotypes of dengue virus, antibody-dependent enhancement is thought to enha
46 ge expressing broadly neutralizing influenza virus antibodies derived from a subject immunized with t
47 nd plasma samples were collected for anti-JC virus antibody detection using an analytically validated
48                 We investigated whether Zika virus antibodies enhance dengue virus replication, by ex
49               After a final boost with whole virus, antibody-expressing hybridomas were generated.
50 isolate B cells whose genes encode influenza virus antibodies from a patient vaccinated for avian inf
51       Patients who were positive for anti-JC virus antibodies, had taken immunosuppressants before th
52                          We showed that Zika virus antibodies have the ability to enhance dengue viru
53 e, 184 samples were tested via ELISA for RVF virus antibodies (IgG and IgM), while all 200 were scree
54     Despite high concentrations of anti-mpox virus antibodies in the plasma, cross-neutralisation act
55 ize infants with maternally acquired measles virus antibodies in whom the current parenterally admini
56 m the NHANES sampling frame have hepatitis C virus antibody, including 500,000 incarcerated people, 2
57              We create two spatial models of virus-antibody interaction and show that for realistic p
58               We use a mathematical model of virus-antibody interaction to elucidate the conditions u
59 -4 to determine how gB-NT contributes to the virus-antibody interaction.
60                        Structural studies of virus-antibody interactions can offer insights into mech
61 c studies showed that these mutations affect virus-antibody interactions during postbinding steps of
62 f two highly efficacious anti-H5N1 influenza virus antibodies into a bispecific FcDART molecule, whic
63                          Detection of dengue virus antibodies is important for understanding future d
64  of action of broadly protective influenza B virus antibodies is required to inform vaccine developme
65                  Adjustment for Epstein-Barr virus antibody levels and C-reactive protein levels had
66 edule was associated with protective measles virus antibody levels at 24 months of age in nearly all
67 months of age, 75% had nonprotective measles virus antibody levels.
68 hat like other heterosubtypic anti-influenza virus antibodies, MAb 3.1 contacts a hydrophobic groove
69             Reports suggest that anti-dengue virus antibody may enhance Zika virus replication.
70 i-human immunoglobulin G Fab fragment to the virus-antibody mixture prior to infection.
71 moreover, SM E041 was simian T-cell leukemia virus antibody negative.
72 pared their diagnostic efficacies by using B virus antibody-negative (n = 40) and -positive (n = 75)
73 ing immune (C-Reactive Protein, Epstein-Barr Virus antibodies), neuroendocrine (cortisol, DHEA-s), an
74       In contrast to genetically inactivated virus, antibody-neutralized virus did not induce diarrhe
75 000, were routinely screened for hepatitis C virus antibody on admission.
76 between 9 and 24 months of age for influenza virus antibodies, performed HI tests for the positive se
77                                      Many JC virus antibody-positive relapsing-remitting multiple scl
78 atients switching from natalizumab due to JC virus antibody positivity at 3 Swedish multiple sclerosi
79 tients who switch from natalizumab due to JC virus antibody positivity.
80                                       Rabies virus antibodies present in serum and cerebrospinal flui
81 TIFY-1 will confirm the stability of anti-JC virus antibody prevalence over time.
82     At baseline (n = 1,096), overall anti-JC virus antibody prevalence was 56.0% (95% confidence inte
83  age and male gender with increasing anti-JC virus antibody prevalence.
84 e or negative status with respect to anti-JC virus antibodies, prior or no prior use of immunosuppres
85 ors: positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and i
86      Positive status with respect to anti-JC virus antibodies, prior use of immunosuppressants, and i
87 rbent assay-determined specific Epstein-Barr virus antibody profiles had a sensitivity and specificit
88 eral B cell subsets and revealed the anti-BK virus antibody repertoire as clonally complex with respe
89 acterize different aspects of the anti-mumps virus antibody response after vaccination.
90                        We tested the measles virus antibody response at 4.5, 9, 18, and 24 months of
91 placed to target the same DLN, the influenza virus antibody response is enhanced.
92 role of polyreactivity during anti-influenza virus antibody responses.
93 e of host genetic and non-genetic factors on virus antibody responses.
94 ffect on the ability to mount anti-influenza virus antibody responses.
95 ith vaccination, recovery of vaccine-related virus, antibody responses, and immunohistochemical assay
96 t myelin destruction in the presence of anti-virus antibodies results from a combination of complemen
97                            We collected 1933 virus-antibody sequences and their clinical patient neut
98 w tools for risk stratification including JC-virus antibody status, prior immunosuppression, and leng
99          During infection with non-enveloped viruses, antibodies stimulate immunity from inside cells
100 zation is highly effective against cell-free virus, antibodies targeting different sites of envelope
101 amples consecutively submitted for West Nile virus antibody testing during 2 days of the 2003 West Ni
102     Blood samples were available for anti-JC virus antibody testing from 5896 patients with multiple
103 ase in the cell-grown influenza A/Washington virus antibody titer (3C.2a2) was protective (60% reduct
104                                  The measles virus antibody titer, however, is a potency requirement
105 63 resulted in a decrease in average measles virus antibody titers among plasma donors, which is refl
106 combination with M8 increased anti-influenza virus antibody titers and protected animals from lethal
107           To mitigate the decline in measles virus antibody titers in IVIGs and to ensure consistent
108                         Neutralizing measles virus antibody titers were above the threshold for prote
109 ated with increased pulmonary anti-influenza virus antibody titers, and this was dependent upon the p
110 ed subjects developed protective anti-rabies virus antibody titers.
111 s been demonstrated to regulate neutralizing virus antibody titers.
112 fants had a similar transplacental influenza virus antibody transfer ratio, lower titers, and a lower
113                                           JC virus antibodies were found in 5 of 13 patients.
114 .3%) (P > 0.05), while hepatitis A, B, and C virus antibodies were more prevalent in the high-risk gr
115 f an inverse association of varicella-zoster virus antibodies with adult onset glioma.
116 r cardiac troponin I and an anti-hepatitis B virus antibody with the high sensitivity required to det
117 g the patients who were negative for anti-JC virus antibodies, with the incidence estimated to be 0.0

 
Page Top